炎症性肠病诱导治疗期间维得利珠单抗低谷浓度与6个月内需额外给药的相关性
该观察性研究纳入法国2家医院47例既往肿瘤坏死因子拮抗剂治疗失败的克罗恩病(31例)或溃疡性结肠炎(16例)患者,予维得利珠单抗300mg诱导治疗。第6周谷浓度<18.5 μg/mL与6个月内需延长治疗相关(阳性预测值100%,阴性预测值46.2%,ROC曲线下面积0.72);第10周需延长治疗且第6周谷浓度<19.0 μg/mL者4周后均达临床缓解。
要点
- 第6周维得利珠单抗谷浓度<18.5 μg/mL与6个月内需延长治疗相关,阳性预测值100%、阴性预测值46.2%。
- 第2周谷浓度在需延长治疗组为23.0 μg/mL,无需延长治疗组为42.5 μg/mL(P=0.15)。
- 第10周接受延长治疗且第6周谷浓度<19.0 μg/mL的患者4周后均达临床缓解。
核心结论
- 克罗恩病或溃疡性结肠炎患者维得利珠单抗诱导治疗第6周谷浓度<19.0 μg/mL与需在第10周及之后每4周额外给药相关。
- 接受上述额外给药的患者4周后均达临床缓解。
研究设计与样本
- 观察性研究,纳入法国2家医院2014年6月至2016年4月连续47例既往2种肿瘤坏死因子拮抗剂治疗失败的克罗恩病(n=31)或溃疡性结肠炎(n=16)患者。
- 所有患者在第0、2、6周给予维得利珠单抗300mg输注,之后每8周给药,并在最初4-6周给予糖皮质激素。
- 第6周未缓解者于第10周给予额外剂量,之后每4周给药(延长治疗或优化治疗)。
- 每周采集血样,以酶联免疫吸附试验检测维得利珠单抗及抗维得利珠单抗抗体血清水平。
主要发现
- 第6周应答评估显示47例中30例需延长治疗(克罗恩病23例,溃疡性结肠炎7例)。
- 第2周谷浓度:需延长治疗组为23.0 μg/mL(四分位距14.0-37.0 μg/mL),无需延长治疗组为42.5 μg/mL(四分位距33.5-50.7 μg/mL),P=0.15。
- 第6周谷浓度<18.5 μg/mL与6个月内需延长治疗相关,阳性预测值100%,阴性预测值46.2%,受试者工作特征曲线下面积0.72。
- 第10周需延长治疗且第6周谷浓度<19.0 μg/mL的患者4周后均达临床缓解(继发应答者)。
关键数值与推荐
- 第6周缓解定义:克罗恩病患者克罗恩病活动指数评分<150分;溃疡性结肠炎患者部分Mayo临床评分<3分且未合用糖皮质激素。
- 第6周谷浓度<18.5 μg/mL用于预测6个月内需延长治疗,阳性预测值100%,阴性预测值46.2%,曲线下面积0.72。
- 第6周谷浓度<19.0 μg/mL与第10周延长治疗后4周临床缓解相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin α4β7, during the induction phase of treatment can determine whether patients will need additional doses (optimization of therapy) within the first 6 months. METHODS: We conducted an observational study of 47 consecutive patients with Crohn's disease (CD; n = 31) or ulcerative colitis (UC; n = 16) who had not responded to 2 previous treatment regimens with antagonists of tumor necrosis factor and were starting therapy with vedolizumab at 2 hospitals in France, from June 2014 through April 2016. All patients were given a 300-mg infusion of vedolizumab at the start of the study, Week 2, Week 6, and then every 8 weeks; patients were also given corticosteroids during the first 4-6 weeks. Patients not in remission at Week 6 were given additional doses of vedolizumab at Week 10 and then every 4 weeks (extended therapy or optimization). Remission at Week 6 of treatment was defined as CD activity score below 150 points for patients with CD and a partial Mayo Clinic score of <3 points, without concomitant corticosteroids, for patients with UC. Blood samples were collected each week and serum levels of vedolizumab and antibodies against vedolizumab were measured using an enzyme-linked immunosorbent assay. Median trough levels of vedolizumab and interquartile ranges were compared using the nonparametric Mann-Whitney test. The primary objective was to determine whether trough levels of vedolizumab measured during the first 6 weeks of induction therapy associated with the need for extended treatment within the first 6 months. RESULTS: Based on response to therapy at Week 6, extended treatment was required for 30 of the 47 patients (23 patients with CD and 7 patients with UC). At Week 2, trough levels of vedolizumab for patients selected for extended treatment were 23.0 μg/mL (interquartile range, 14.0-37.0 μg/mL), compared with 42.5 μg/mL in patients who did not receive extended treatment (interquartile range, 33.5-50.7; P = .15). At Week 6, trough levels of vedolizumab <18.5 μg/mL were associated with need for extended therapy (100% positive predictive value, 46.2%; negative predictive value; area under the receiver operating characteristic curve, 0.72) within the first 6 months. Among patients who required extended treatment at Week 10, all of those with trough levels of vedolizumab <19.0 μg/mL at Week 6 had achieved clinical remission 4 weeks later (secondary responders). CONCLUSIONS: In a prospective study of patients with CD or UC receiving induction therapy with vedolizumab, low trough levels of vedolizumab at Week 6 (<19.0 μg/mL) are associated with need for additional doses (given at Week 10 and then every 4 weeks). All patients receiving these additional doses achieved a clinical response 4 weeks later.
引用
- Williet N, Boschetti G, Fovet M, et al. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. Clin Gastroenterol Hepatol. 2016. PMID: 27890854. doi:10.1016/j.cgh.2016.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。